Future Challenges in Cancer Resistance to Immunotherapy
Cancer immunotherapies, including checkpoint inhibitors, adoptive T cell transfer and therapeutic cancer vaccines, have shown promising response rates in clinical trials. Unfortunately, there is an increasing number of patients in which initially regressing tumors start to regrow due to an immunothe...
Main Authors: | Marit J. van Elsas, Thorbald van Hall, Sjoerd H. van der Burg |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/4/935 |
Similar Items
-
Mechanisms of Cancer Resistance to Immunotherapy
by: Rilan Bai, et al.
Published: (2020-08-01) -
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
by: Dhruv Bansal, et al.
Published: (2021-01-01) -
TEIPP peptides: exploration of unTAPped cancer antigens
by: Koen A. Marijt, et al.
Published: (2019-08-01) -
The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy
by: Els M. E. Verdegaal, et al.
Published: (2017-09-01) -
Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
by: Lisa C. Holthof, et al.
Published: (2020-04-01)